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ated with a lower total cost (€ 1,562) and a larger health gain (QALYs) at one year 
(0.732) per patient, and dominated the other treatment strategies since more QALYs 
were achieved at a lower total cost. Sensitivity analyses support the robustness of 
the model. ConClusions: The results indicate that escitalopram is the most cost-
effective pharmacological treatment strategy for the Italian health service compared 
with other SSRIs and all SNRIs used in the first-line treatment of MDD.
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objeCtives: Paliperidone palmitate has demonstrated non-inferior efficacy to 
risperidone long acting injectable (LAI) for the treatment of schizophrenia in previ-
ous studies. The objective of this analysis was to assess the cost effectiveness of 
paliperidone palmitate relative to risperidone LAI, based on the cost-utility analysis 
described in the current NICE Guidelines for the Management of Schizophrenia. The 
analysis was undertaken from the perspective of NHS Wales and was submitted to 
the All Wales Medicines Strategy Group for evaluation. Methods: A decision-ana-
lytic Markov model was developed to estimate the cost-utility of paliperidone palmi-
tate relative to risperidone LAI. The model adopted an annual cycle length. Patients 
who entered the model initiated either paliperidone palmitate or risperidone LAI 
and could subsequently transition between five health states during each annual 
cycle. AEs associated with each intervention were derived from literature. Utility 
values were derived from a community-based study, using trade-off technique to 
elicit HRQoL for schizophrenia according to frequency of injections. Resource use 
data was sourced from the NICE core model/guidelines, Welsh clinical experts, and 
a UK Delphi panel. Unit costs were derived from the British National Formulary, NHS 
reference costs, and the Personal Social Services Research Unit reports. Costs and 
outcomes were evaluated over a 10-year horizon, and discounted at 3.5%. Results 
were presented as incremental costs/QALY. Uncertainty was addressed via deter-
ministic and probabilistic sensitivity analyses. Results: The base case analyses 
demonstrated that paliperidone palmitate would incur lower costs (-£3,773) and 
generate more quality adjusted life years (QALYs) (+0.13) than risperidone LAI. This 
indicated that paliperidone palmitate ‘dominated’ risperidone LAI. Extensive sce-
nario/sensitivity analyses confirmed the robustness of the results ConClusions: 
Compared with risperidone LAI, paliperidone palmitate is a cost-effective therapy 
for the treatment of schizophrenia in adult patients in NHS Wales.
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objeCtives: Major depressive disorder (MDD) causes a massive health and eco-
nomic burden for societies worldwide. Cognitive behavioural therapy (CBT) is an 
inherent part of the treatment of MDD and is recommended for children, adoles-
cents and adults. Cost-Utility-Analysis (CUA) is an important instrument to sup-
port decision-making on resource allocation and health policy as it permits the 
comparison of interventions for different diseases. The objective of our study was 
to systematically review CUAs related to CBT in the treatment of patients suffering 
from MDD. Methods: We conducted a systematic literature search in MEDLINE, 
EMBASE, PsycINFO and NHSEED. We included all original studies reporting CUA of 
CBT for patients suffering from MDD. Cost data were inflated to the year 2011 and 
converted into US-$ using purchasing power parities (US-$ PPP) to ensure compa-
rability of the data. Quality assessment of the studies was performed by means of 
a standardised quality checklist. Results: We identified 22 CUAs. The methodo-
logical quality was fair. Two studies considered a lifetime horizon. The mean time 
horizon of the remaining studies was 19.2 months (SD = 12.6). In most instances 
individual and group CBT as well as CBT for maintenance showed acceptable cost-
utility ratios (ICER < 50.000 US-$-PPP / QALY). The results of CUAs of CBT provided 
for children and adolescents or by computer were inconsistent. In comparison 
to medication CBT tends to be more cost effective as stand-alone therapy and in 
combination with medication. ConClusions: Individual and group CBT is a cost 
effective treatment for MDD. Further research to determine the cost effectiveness 
of computerized CBT and of CBT for specific populations like children, adolescents 
or the elderly is required. Furthermore there is a need for long term evidence of 
cost effectiveness of CBT.
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objeCtives: This study compared health care resource utilization (HRU) and costs 
among children/adolescents with attention deficit/hyperactivity disorder (ADHD) 
in Germany who initiated treatment with atomoxetine (ATX) or long-acting meth-
ylphenidate (LA-MPH). Methods: A retrospective propensity score matched cohort 
analysis was conducted using the IMS electronic medical record database compris-
ing > 15 million patient records from ~3,000 German physicians. Included patients 
were aged 6-17 years, with a first (index) ATX or LA-MPH prescription in 2006-2010; 
≥ 1 ADHD diagnoses 12-month before (pre-index) and after (post-index) index; and 
≥ 1 index medication prescription post-index. Patients in the ATX and LA-MPH 
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objeCtives: An economic analysis was conducted from the United Kingdom’s 
(UK’s) National Health Service (NHS) perspective to evaluate the cost-effectiveness 
of lisdexamfetamine (LDX) versus atomoxetine (ATX) in treating children and 
adolescents with attention-deficit/hyperactivity disorder (ADHD) who have had 
an inadequate response to methylphenidate (MPH). Methods: A 1-year proba-
bilistic decision-analytic model with a Markov structure of nested decision trees 
was constructed. Health states included “response”, “non-response”, and “unable 
to tolerate”. Key model assumptions were adapted from a technology assessment 
for ADHD products by the National Institute for Health and Care Excellence. The 
analysis used clinical data from a head-to-head randomized controlled trial in inad-
equate responders to MPH. Response to treatment was defined as a score of 1 (much 
improved) or 2 (improved) on the Clinical Global Impression-Improvement scale. 
Tolerability was assessed by rates of discontinuation due to adverse events. Utility 
weights were identified via a systematic literature review. Health care resource use 
estimates for responders and non-responders were obtained via a survey of UK spe-
cialists. Unit costs from national sources were applied to estimate the correspond-
ing health-state costs. Daily drug costs were based on mean doses reported in the 
trial. One-way and probabilistic sensitivity analyses were performed. Results: The 
comparison of LDX and ATX, using head-to-head data, resulted in an incremental 
cost-effectiveness ratio (ICER) of £1,802 per quality-adjusted life year (QALY). At a 
willingness to pay of £20,000 per QALY, LDX had an 86% probability of being cost-
effective compared with ATX. In 38% of sensitivity analysis runs, LDX was a domi-
nant strategy over ATX. The model was slightly sensitive to changes in assumptions 
about drug costing and to lengthening the titration period for ATX. ConClusions: 
From the perspective of the UK NHS, LDX provides a cost-effective treatment option 
for children and adolescents with ADHD who are inadequate responders to MPH.
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objeCtives: The cost-effectiveness of second-generation antipsychotic drugs 
is well established in the treatment of patients experiencing a manic episode 
associated with bipolar I disorder. However, no studies demonstrating the value of 
these drugs in patients with mixed episodes according to DSM-IV have so far been 
undertaken. The aim of this study was to assess the cost-effectiveness of asenapine 
versus olanzapine in the treatment of this costly subgroup of patients. Methods: 
A 9-week acute phase model was developed, during which patients receive up to 
three lines of treatment: asenapine or olanzapine alone, then adjunctive valproate, 
and finally a switch to adjunctive lithium. Patients can respond during any 3-week 
period and non-responders move to the next treatment in the sequence. Efficacy of 
asenapine (46.3%) and olanzapine (37.5%) was informed by a post-hoc analysis of 
two short-term clinical trials, where response was measured as a composite YMRS 
and MADRS endpoint. Following initial treatment, patients entered a 5-year main-
tenance Markov model during which they faced probabilities of treatment discon-
tinuation, recurrent manic, mixed and depressive symptoms and death. Direct costs 
(year 2012-13 values), including drug, monitoring costs and resource use related to 
bipolar disorder and selected adverse events, were assessed from a UK NHS per-
spective. Benefits were measured as quality-adjusted life years (QALYs). Results: 
For patients with a mixed episode, asenapine was a more effective and less costly 
treatment strategy compared with olanzapine over a 5-year period. Greater health 
benefits and cost savings were driven by earlier response to asenapine treatment 
during the acute phase and were well maintained during longer-term follow-up. 
These results were robust to changes in key parameters including short and longer-
term efficacy, unit cost and utility values. ConClusions: Compared with olanzap-
ine, results of this analysis suggest that asenapine generates greater health benefits 
at lower cost in the treatment of patients experiencing mixed episodes associated 
with bipolar I disorder.
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objeCtives: To assess the cost-effectiveness (€ per quality-adjusted life year [QALY]) 
of all Selective serotonin reuptake inhibitors (SSRIs) and all Serotonin-norepinephrine 
reuptake inhibitors (SNRIs) for the treatment of Major Depressive Disorder (MDD) in 
Italy. Methods: A decision analytic model was adapted from the Swedish Dental 
and Pharmaceutical Benefits agency model to reflect current clinical practice in the 
treatment of MDD in the largest Italian regions. This adaptation was possible thanks 
to the collaboration of an expert panel of Italian psychiatrists and health economists. 
The model evaluated patients with a first diagnosis of MDD and initiating an SSRI 
or an SNRI for the first time. The time horizon was 12 months. Efficacy and utility 
data for the model were retrieved from the literature and validated by the expert 
panel. Local data were considered for resource utilization and for treatment costs 
based on each regional health service perspective. Population-weighted regional 
data were used to define a national model. Scenario simulations, one-way sensitiv-
ity analyses, and Monte Carlo simulations were performed to test the robustness of 
the model. Results: The base case analysis showed that escitalopram was associ-
A550  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
Copenhagen, Denmark, 5The Zucker Hillside Hospital and the Hofstra North Shore-LIJ School of 
Medicine, Hempstead, NY, USA
objeCtives: To evaluate functional outcomes of aripiprazole once-monthly 
(ARI-OM) 400 mg (ARI-OM-400) versus a sub-therapeutic dose of ARI-OM (50 mg; 
ARI-OM-50), oral aripiprazole (ARI), and placebo, in two trials of stable patients with 
schizophrenia. Methods: Detailed study designs have been reported previously. 
Results are reported for the double-blind, randomized phase of each study. ARI-OM 
is an extended-release injectable suspension given at 400 mg in the gluteal muscle. 
Functional outcome was measured using the Personal and Social Performance scale 
(PSP) and statistically analyzed using analysis of covariance with last observation 
carried forward. Results: A total of 403 patients were randomized to ARI-OM-400 
(n= 269) or placebo (n= 134) in the first (246) trial. PSP scores at endpoint significantly 
worsened with placebo (-6.2) versus ARI-OM-400 (-1.7; p= 0.0002). In the second 
study (247), 662 patients were randomized to: ARI-OM-400 (n= 265); ARI (n= 266); 
or ARI-OM-50 (n= 131). PSP scores with sub-therapeutic ARI-OM-50 significantly 
worsened (-2.39) versus ARI-OM-400 (+0.45; p= 0.03). Similar functional stability 
was observed with ARI (+0.08). ConClusions: Patient functioning, as assessed 
by PSP, was maintained with ARI-OM in both studies but deteriorated in patients 
randomized to either sub-therapeutic doses or placebo, confirming the benefits of 
adequately dosed antipsychotic therapy in preserving functional stability in long-
term management of schizophrenia.
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objeCtives: Mild cognitive impairment (MCI) is a state that lies between normal 
cognition and dementia, and the number of cases with the condition is rising as the 
population ages. However, to date, no validated patient reported outcome measure 
(PRO) exists specifically in MCI. We report on a study to develop a PRO for use in 
MCI. Methods: Semi-structured in-depth interviews were carried out with peo-
ple with MCI in order to determine the questionnaire items. These interviews were 
audio-recorded, transcribed and content analysed. The draft questionnaire was 
refined following feedback from a focus group of patients with a diagnosis of MCI. 
Questionnaires were posted to subjects recruited from memory clinics and research 
databases, the completed questionnaires were analysed using factor analytic tech-
niques to produce the final measure; construct validity was assessed by correlation 
with a generic patient reported outcome measure, the SF-12. Results: Interviews 
were carried out with 23 people with MCI. 280 questionnaires were sent to subjects, 
with a response rate of 56% i.e.146 were included in the analysis. Factor analysis 
produced a 13 item measure tapping two domains of patient reported quality of life 
(‘Emotional Effects’ and ‘Practical Concerns’ ). Internal consistency reliability was high 
for both domains (alpha was 0.91 and 0.85 respectively). Both dimensions were found 
to be highly and significantly correlated with the Mental Component Summary score 
of the SF-12. ConClusions: The Mild Cognitive Impairment Questionnaire (MCQ) is 
a short 13 item measure developed specifically to measure patient reported outcomes 
in people with MCI. It was created on the basis of patient report, and has been shown 
to have good psychometric properties. It is likely to prove valuable in the evaluation 
of treatment regimes in this important and growing patient group.
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objeCtives: To guide researchers on the best way to score the Center for 
Epidemiologic Studies – Depression scale (CES-D) by comparing competing mod-
els in the literature. Methods: Radloff (19777), the original CES-D author, first 
provided scoring for four uncorrelated factors of depression: negative affect 
(NA), positive affect (PA), interpersonal (I), and somatic (S). Sheehan et al. (1995) 
validated four correlated factors in the CES-D. However, Radloff and Sheehan 
results may have differed because Radloff ascribed items of failure and fearfulto 
NA whereas Sheehan assigned a value of I. Following Sheehan’s scoring, Cole et 
al. (2004) presumed a hierarchical factor of depressed mood that included all four 
previously identified factors and posited a 10-item short-form of the CES-D. These 
four models were compared using structural equation modeling for parametric 
models with Bollen-Stine bootstraps to control for multivariate nonnormality in 
225 community-residing subjects, structural validity of the models were com-
pared. Results: Fit statistics for the four models were: Radloff comparative fit 
index (CFI) = .790 & root mean square error of approximation (RMEA) = .011; 
Sheehan CFI = .926 & RMSEA = .053, Cole hierarchical CFI = .927 & RMSEA = 
.052; Cole 10-item CFI = .979 & RMSEA = .041 ConClusions: The uncorrelated 
Radloff model was the poorest fit the day. Both Sheehan and Cole 20-item models 
were decently fit to the data and nearly identical to each other in fit. Finally, the 
10-item Cole short-form of the CES-D was the best fit model to the data. Given 
the brevity of this form and strong fit with the theoretical structure postulated 
by Radloff, researchers may want to consider this form of the CES-D for research 
on depressed mood.
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objeCtives: Although depression is a significant co-morbid condition in chronic 
illness, little is known about the prevalence or risk factors for depressive symp-
cohorts were matched 1:1 using “nearest neighbor” greedy match propensity score 
method. HRU (inpatient, outpatient, and medications) and costs were compared 
between the two cohorts. Unit costs were identified from German Diagnosis-related 
Group for inpatient, Einheitlicher Bewertungsmassstab doctor fee scale for out-
patient, and Rote Liste®for medication costs. Direct medical costs over the post-
index period were reported in 2011 Euros. Chi-square for categorical variables and 
t-test or Wilcoxon-Mann-Whitney for continuous variables were used to test for 
differences between cohorts (alpha= 0.05). Generalized linear models with nega-
tive binomial (for HRU) and gamma (for cost) distributions were used to address 
residual differences between matched cohorts. Results: Of 4705 eligible patients, 
737 with ATX (mean age= 10.9 years, 20.8% female) were identified and matched 
1:1 with LA-MPH patients (mean age= 11.2 years, 18.6% female). Patients initiating 
ATX had higher HRU and spending per-patient than patients initiating LA-MPH 
over the post-index: 20.9 (SD= 11.5) vs. 15.7 (SD= 9.0) outpatient prescriptions, 10.1 
(SD= 6.3) vs. 8.3 (SD= 5.3) outpatient visits, € 1029 (SD= 574) vs. € 496 (SD= 334) in retail 
pharmacy costs, and € 1,258 (SD= 739) vs. € 684 (SD= 515) in total all-cause costs (all 
p= < .0001). ConClusions: Among children/adolescents with ADHD in Germany, 
ATX initiators consumed significantly more health care resources and were associ-
ated with significantly higher direct medical costs compared with LA-MPH initiators.
MEntal HEaltH – Patient-reported outcomes & Patient Preference studies
PMH48
faCtors assoCiatEd WitH Poor adHErEnCE in PatiEnts initiating 
MEdiCation for Major dEPrEssivE disordEr: intEriM rEsUlts froM a 
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objeCtives: To examine factors associated with low adherence in Major Depressive 
Disorder (MDD) patients initiating antidepressant medication (ADM) over a 12-week 
period. Methods: MDD patients initiating an ADM (with no ADM claim in the 6 
months prior) were identified from a large pharmacy benefits manager database. 
Patients completed paper or online assessments including demographics at baseline 
and patient-reported assessments at baseline, Week 4 and Week 12. Participants were 
classified as having low, medium, or high adherence based on the modified Morisky 
Adherence Scale, with the medium and high adherence groups combined for analysis. 
Logistic regression analyses were run to evaluate the association between adherence 
and age, gender, and patient-reported assessments of depression and sexual dysfunc-
tion (SD), weight gain, sleep problems, nausea, and anxiety. Results: Of 2412 patients 
screened, 591 enrolled and completed baseline assessments. Mean age was 40.4 years 
(standard deviation= 12.1), 82.4% were women, and 87.6% were white. There were 483 
who completed Week 4 and 425 who completed Week 12 assessments. At Week 12, 
39.6% were high adherers, 20.6% were medium adherers, and 39.8% were low adher-
ers. Thirty-eight percent of low adherers had actually discontinued ADM. Among dis-
continuers, 40.6% discontinued due to ADM side effects. In logistic regression models, 
low adherence at Week 4 was significantly associated with weight change ≥ 5 pounds 
(OR= 2.10, 95% CI: 1.32–3.35), anxiety (OR= 1.73, 95% CI: 1.06-2.8) and nausea (OR= 2.31, 
95% CI: 1.06–5.02). Age, gender, depression severity, sexual dysfunction, and insomnia 
were not significant in the logistic model. No factors were significantly associated 
with adherence at Week 12. ConClusions: In this real-world study of patients with 
MDD, nearly 40% of patients were low adherers. Weight change, anxiety, and nausea 
were associated with low adherence at Week 4, but not at Week 12.
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objeCtives: This study examined patterns of adherence, switching, and discontinu-
ation, in major depressive disorder (MDD) patients initiating antidepressant medica-
tion (ADM) therapy. Methods: Depressed patients recently initiating an ADM were 
identified from a large pharmacy benefits manager database. Eligible patients were 
invited to participate by phone or mail and enrolled patients completed. Results: 
Of 2,412 patients screened, 591 were enrolled. Average age was 40.4 years (standard 
deviation= 12.1), 82.4% of participants were women, and 87.6% were white. At Week 
4 (n= 483), 39.4% were classified as low adherers with 31 (6.4%) patients having 
discontinued ADM for reasons including side effects (n= 14, 45.2%), feeling better 
(n= 5, 16.1%), cost (n= 5, 16.1%), and lack of efficacy (n= 4, 12.9%). There were 27 (5.6%) 
patients who switched by Week 4. Of these, 12 (44.4%) switched due to side effects, 
11 (40.7%) due to lack of efficacy, and 3 (11%) due to cost. By week 12 (n= 425), 33 
additional patients had discontinued ADM citing similar reasons as those at Week 
4. Of 43 patients who reported switching at Week 4 or Week 12, 15 (34.9%) cited side 
effects, 16 (37.2%) cited lack of efficacy, and 4 (9.3%) cited cost. ConClusions: In 
this real-world, 12-week study of MDD patients initiating ADM, adherence to ADM 
was low. Switching and discontinuing ADM were common within the 12-weeks 
period and were primarily attributed to side effects and lack of efficacy.
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